University of California

Princeton University

Leland Stanford Junior University

Other

Icahn School of Medicine at Mount Sinai

Mitokinin, Inc.

Washington University

University Technologies International, Inc.

Intellikine LLC

Quorex Pharmaceuticals, Inc.

Mount Sinai School of Medicine

Fundacion Ciencia Para La Vida

Kevan M Shokat

Chao Zhang

Jonathan Ostrem

Ulf Peters

Arvin C Dar

Jeffrey S Glenn

Ingrid Choong

Michael A Gelman

Brandon Tavshanjian

Masanori Okaniwa

Mark Smith

Bonnie L Bassler

Michael G Surette

Michael S Cohen

Peter Walter

Stephan Schauder

Nicholas T Hertz

Beth Apsel

Zachary A Knight

Alexei Korennykh

Robert J DeVita

Jeffrey D Stein

Robert M Stroud

Ross L Cagan

Steven Moss

Sebastian Bernales

Jack Taunton

Andrei Korostelev

Pascal Egea

Janet Finer-Moore

Carol Dammel

Trever G Bivona

Martin Sos

Tirtha K Das

Daniel Gentile

Yi Liu

Pingda Ren

Liansheng Li

Troy Edward Wilson

Katrina Chan

James Walter Janetka

Stephen Gregory DiMagno

Andrew Gaheem Hsieh

Robert Joseph Devita

Christian Rommel

Heinz W Gschwend

Alma L Burlingame

Nikolai Sepetov

Eric J Kunkel

John William Taunton

Laurence David Sibley

Davide Ruggero

Masahiro Tanaka

Anthony Bishop

Kirk Hansen

Raynard L Bateman

Morris Feldman

Han Li

Florentine Rutaganira

Justin Gabriel Meyerowitz

William Clay Gustafson

William A Weiss

Christopher Novotny

Natalia Jura

David Fruman

David Pearce

Matthew Janes

Olusegun Williams

Adam L Garske

Matthew D Simon

Steve Worland

Merritt Edlind

James Appleman

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

Compositions and methods for treating cancer

Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.

mTORC1 inhibitors

Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribavirin, and the like.

PI-kinase inhibitors with anti-infective activity

Mtorc1 inhibitors

Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.

Compositions and methods for treating neurodegenerative diseases and cardiomyopathy

Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.

Compositions and methods for treating parasitic diseases

Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.

Aurora kinase inhibitors

Described herein, inter alia, are compositions of HER3 ligands and methods for treating diseases using the same.

HER3 ligands and uses thereof

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.

Growing community of inventors

San Francisco, CA, United States of America

Kevan M Shokat